Baudax Bio's share price could stay at $14.00 by May 11, 2021. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Click here to watch the full series. Zacks Rank Education -- Learn more about the Zacks Rank . If you had invested in Baudax Bio stock at $7.00, your return over the last 1 years would have been -81.43%, for an annualized return of -81.43%. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. Delayed quotes by Sungard. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Share your opinion and gain insight from other stock traders and investors. Baudax Bio. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. According to 3 analysts, the average rating for Baudax Bio stock is "Buy." Price Target Get the latest Baudax Bio Inc (BXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The Company's lead … Press Release Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules Published: Feb. 8, 2021 at 3:25 p.m. No cost, no obligation to buy anything ever. On average, Wall Street analysts predict that . Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Post-Market 0.00 (0.00%) Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. It focuses on the development and commercialization of products for acute care settings. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Baudax Bio News: BXRX Stock Soars 15% on FDA Drug Approval By William White, InvestorPlace Writer Feb 21, 2020 Baudax Bio (BXRX) news for Friday surrounding approval from the U.S. Food & … See rankings and related performance below. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA … Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. See Zacks' prediction free. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. The stock has traded between $1.70 and $1.95 so far today. Find the latest Baudax Bio, Inc. (BXRX) stock discussion in Yahoo Finance's forum. Research, Inc. nor its Information Providers can guarantee the accuracy, A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. For all future releases Just for the upcoming release Send me a reminder 1 trading day before Detailed statistics for Baudax Bio (BXRX) stock, including valuation metrics, financial numbers, share information and more. Zacks Style Scores Education - Learn more about the Zacks Style Scores. MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri … Oppenheimer Releases a Buy Rating on Baudax Bio (BXRX). Warrants. Please see full Prescribing Information for ANJESO, including Important Safety Information and Boxed Warning, at www.anjeso.com. Baudax Bio, Inc. operates as a pharmaceutical company. Get the hottest stocks to trade every day before the market opens 100% free. The monthly returns are then compounded to arrive at the annual return. Log in to see them here or sign up to get started. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. GlobeNewswire 22d: Baudax Bio EPS misses … Baudax Bio expects to raise $17.6 million in a direct stock offering scheduled to close mid-week. Get the latest Baudax Bio, Inc. BXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. This browser is no longer supported at MarketWatch. Earnings for Baudax Bio are expected to grow in the coming year, from ($1.26) to ($0.75) per share. Baudax Bio's share price could stay at $14.00 by May 11, 2021. Baudax Bio to Report 2020 Annual Financial Results and Host Conference Call and Webcast on February 16, 2021 • Feb 10, 2021 Baudax Bio Announces $17.6 Million Offering Priced At-the-Market … Baudax Bio, Inc. operates as a pharmaceutical company. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. ET Get the latest Baudax Bio detailed stock quotes, stock trade data, stock price info, and performance analysis, including Baudax …